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ABBREVATIONS 
 
 
 
 
BAEP  –  BRAINSTEM AUDITORY EVOKED POTENTIAL. 
CMAP –   COMPOUND MUSCLE ACTION POTENTIAL. 
CNS  –  CENTRAL NERVOUS SYSTEM. 
DM  –  DIABETES MELLITUS. 
DN –   DIABETIC NEUROPATHY 
MODY – MATURITY ONSET DIABETES OF THE YOUNG 
NCV  –   NERVE CONDUCTION VELOCITY. 
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INTRODUCTION 
Diabetes mellitus (DM) comprises a group of common metabolic 
disorders that share the phenotype of hyperglycaemia. Several distinct 
types of DM exist and are caused by a complex interaction of genetics, 
environmental factors, and life-style choices. Depending on the aetiology 
of the DM, factors contributing to hyperglycaemia may include reduced 
insulin secretion, decreased glucose utilization, and increased glucose 
production1. The metabolic dysregulation associated with DM causes 
secondary pathophysiologic changes in multiple organ systems that impose 
a tremendous burden on the individual with diabetes and on the health care 
system. DM is the leading cause of end-stage renal disease (ESRD), 
nontraumatic lower extremity amputations, and adult blindness. With an 
increasing incidence worldwide, DM will be a leading cause of morbidity 
and mortality for the foreseeable future. 
It is estimated that the global number of adults suffering from any 
form of diabetes will reach 285 million in 2010 and further increase to 439 
million in 2030, most of them non insulin dependent diabetes mellitus 
cases 2,3. Globally, type 2 diabetes mellitus has become one of the most 
important chronic public health problems4 . 
BROAD CLASSIFICATION OF DIABETES MELLITUS 
1. Type 1 diabetes also called as insulin dependent DM (IDDM) is caused   
by lack of insulin secretion. 
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2. Type 2 diabetes also called Non insulin dependent DM (NIDDM) is 
caused by   decreased sensitivity of target tissues to the metabolic effect 
of insulin. 
Etiologic Classification of Diabetes Mellitus 1 
I.  Type 1 diabetes (β-cell destruction, usually leading to absolute insulin 
deficiency) 
A. Immune-mediated 
B. Idiopathic 
II.  Type 2 diabetes (may range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly insulin secretory defect 
with insulin resistance) 
III. Other specific types of diabetes 
A. Genetic defects of β-cell function characterized by mutations in: 
     1. Hepatocyte nuclear transcription factor (HNF) 4α (MODY 1) 
 2. Glucokinase (MODY 2) 
 3. HNF-1α (MODY 3) 
 4. Insulin promoter factor (IPF) 1 (MODY 4) 
 5. HNF-1β (MODY 5) 
 6. NeuroD1 (MODY 6) 
 7. Mitochondrial DNA 
 8. Proinsulin or insulin conversion 
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B. Genetic defects in insulin action: 
                  1. Type A insulin resistance 
                  2. Leprechaunism 
                  3. Rabson-Mendenhall syndrome 
                  4. Lipodystrophy syndromes 
C.  Diseases of the exocrine pancreas—pancreatitis, pancreatectomy, 
neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous 
pancreatopathy. 
D. Endocrinopathies-acromegaly, Cushing’s syndrome, glucagonoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma, 
aldosteronoma. 
E.  Drug- or chemical-induced—Vacor, pentamidine, nicotinic 
acid,glucocorticoids, thyroid hormone, diazoxide, β-adrenergic 
agonists,Thiazides, phenytoin, α-interferon, protease inhibitors, 
clozapine,Beta blockers. 
F.  Infections—congenital rubella, cytomegalovirus, coxsackie. 
G.  Uncommon forms of immune-mediated diabetes—―stiff-man‖ 
syndrome, anti-insulin receptor antibodies. 
H.  Other genetic syndromes sometimes associated with diabetes—
Down’s syndrome, Klinefelter’s syndrome, Turner’s syndrome, 
Wolfram’s syndrome, Friedreich’s ataxia, Huntington’s chorea, 
Laurence-Moon-Biedl syndrome, myotonic dystrophy, porphyria, 
Prader-Willi syndrome. 
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IV.  Gestational diabetes mellitus. 
CHRONIC COMPLICATIONS OF DM 
The chronic complications of DM affect many organ systems and 
are responsible for the majority of morbidity and mortality associated with 
the disease. Chronic complications can be divided into vascular and 
nonvascular complications1. 
Chronic Complications of Diabetes Mellitus1 
Microvascular 
 Eye disease. 
 Retinopathy (nonproliferative / proliferative). 
 Macular edema. 
 Neuropathy. 
 Sensory and motor (mono- and polyneuropathy). 
 Autonomic. 
 Nephropathy. 
Macrovascular 
 Coronary artery disease.  
 Peripheral vascular disease. 
 Cerebrovascular disease. 
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Other 
 Gastrointestinal (gastroparesis, diarrhea). 
 Genitourinary (uropathy/sexual dysfunction). 
 Dermatologic. 
 Infectious. 
 Cataracts. 
 Glaucoma. 
The risk of chronic complications increases as a function of the 
duration of disease they usually become apparent in the second decade of 
hyperglycaemia. Since type2 DM often has a long asymptomatic period of 
hyperglycaemia, many individuals with type 2 DM have complications at 
the time of diagnosis1. Chronic complications are the major outcome of 
type 2 diabetes mellitus progress, which reduce the quality of life of 
patients, incur heavy burdens to the health care system, and increase 
diabetic mortality5 
MECHANISMS OF COMPLICATIONS1 
The exact mechanism(s) by which diabetes leads to such diverse 
cellular and organ dysfunction is unknown. Four prominent theories, which 
are not mutually exclusive, have been proposed to explain how 
hyperglycaemia might lead to the chronic complications of DM. 
Advanced Glycosylation End Products (Ages) Theory 
One theory is that increased intracellular glucose leads to the 
formation of advanced glycosylation end products (AGEs) via the 
5 
 12 
 
nonenzymatic glycosylation of intra and extracellular proteins. 
Nonenzymatic glycosylation results from the interaction of glucose with 
aminogroups on proteins. AGEs have been shown to cross-link proteins 
(e.g., collagen, extracellular matrix proteins), accelerate atherosclerosis, 
promote glomerular dysfunction, reduce nitric oxide synthesis, induce 
endothelial dysfunction, and alter extracellular matrix composition and 
structure. The serum level of AGEs correlates with the level of glycaemia, 
and these products accumulate as glomerular filtration rate declines. 
Sorbitol Pathway Theory 
A second theory is based on the observation that hyperglycaemia 
increases glucose metabolism via the sorbitol pathway. Intracellular 
glucose is predominantly metabolized by phosphorylation and subsequent 
glycolysis, but when increased, some glucose is converted to sorbitol by 
the enzyme aldose reductase. Increased sorbitol concentration alters redox 
potential, increases cellular osmolality, generates reactive oxygen species, 
and likely leads to other types of cellular dysfunction. However, testing of 
this theory in humans, using aldose reductase inhibitors, has not 
demonstrated significant beneficial effects on clinical endpoints of 
retinopathy, neuropathy, or nephropathy. 
A third hypothesis proposes that hyperglycaemia increases the 
formation of diacylglycerol leading to activation of protein kinase C 
(PKC). Among other actions, PKC alters the transcription of genes for 
fibronectin, type IV collagen, contractile proteins, and extracellular matrix 
proteins in endothelial cells and neurons. 
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A fourth theory proposes that hyperglycemia increases the flux 
through the hexosamine pathway, which generates fructose-6-phosphate, a 
substrate for O-linked glycosylation and proteoglycan production.The 
hexosamine pathway may alter function by glycosylation of proteins such 
as endothelial nitric oxide synthase or by changes in gene expression of 
transforming growth factor β(TGF-β) or plasminogen activator inhibitor-1 
(PAI-1). 
DIABETES MELLITUS AND PERIPHERAL NERVOUS SYSTEM 
Peripheral nervous system disorders are one of the more frequent 
long-term complications of diabetes mellitus. The clinical features, 
epidemiology and pathophysiology of peripheral diabetic neuropathy have 
been studied extensively. Diabetic neuropathy (DN) occurs in 
approximately 50% of individuals with long-standing type 1 and type 2 
DM. It may manifest as polyneuropathy, mononeuropathy, and/or 
autonomic neuropathy. As with other complications of DM, the   
neuropathy correlates with the duration of diabetes; both myelinated and 
unmyelinated nerve fibers are lost1.  
DN is not a single entity but a number of different syndromes 
ranging from subclinical to clinical manifestation depending on the classes 
of nerve fibres involved. The main groups of neurological disturbance in 
DM include 6. 
1)  Subclinical neuropathy, determined by abnormalities in electro 
diagnostic and quantitative sensory testing. 
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2)  Diffuse clinical neuropathy and distal symmetric sensorimotor and 
autonomic syndromes. 
3)  Focal syndromes. 
The broad diversity of neurologic complications in patients with 
DM can be considered to consist of two distinct types. In one form the 
symptoms and signs are transient, in the other they progress steadily. The 
transient category includes acute painful neuropathies, mononeuropathies 
and radiculopathies. The progressive type comprises sensorimotor 
polyneuropathies with or without autonomic symptoms and signs7. 
The simplest and most widely used classification was initially 
proposed by Thomas8. This approach divides the diabetic neuropathies into 
diffuse, generalized or symmetrical polyneuropathies and focal 
neuropathies. A modification of this neuropathy is shown here9. 
A. SYMMETRIC NEUROPATHIES 
 1. Distal symmetrical sensorimotor polyneuropathy. 
 2. Autonomic neuropathy. 
 3. Acute painful neuropathy. 
 4. Hyperglycemic neuropathy. 
 5. Treatment induced neuropathy. 
 6. Symmetrical proximal lower extremity neuropathy. 
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B. FOCAL AND MULTIFOCAL NEUROPATHY 
 1. Cranial neuropathy. 
 2. Thoraco abdominal neuropathy. 
 3. Focal limb neuropathy. 
 4. Diabetic amyotrophy. 
DIABETES AND CENTRAL NERVOUS SYSTEM 
The involvement of central nervous system (CNS) in DM is recent 
concept. Woltman and Wilder10 concluded from pathological material that 
diabetic neuropathy is a disease of peripheral nerves and that degeneration 
in the CNS is unimportant. However, it is reasonable to ask whether such a 
ubiquitous metabolic derangement and diffuse angiopathy might involve 
any part of the nervous system. Recent studies11 showed the involvement 
of brain parenchyma in patients with long standing diabetes mellitus. 
The central nervous system could also be abnormal in diabetic 
patients12,13,14. De Jong15 has pointed to clinical and pathological evidence 
that the brain parenchyma might be affected. Kent16 has argued that 
diabetic patients show some neurological and psychological symptoms that 
might signify premature aging. The pathophysiology of central nervous 
system (CNS) abnormalities in DM is not well understood, probably many 
causes are responsible for the neural damage, including, chronic 
hyperglycaemia, hypoglycaemic episodes, blood-brain barrier dysfunction, 
angiopathy, and others17,18,19. In diabetic patients, deficits have been 
reported in neuropsychological, neuroradiological and neurophysiological 
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studies. Neuropsychological studies report deficits in cognitive functions, 
in particular learning and memory and complex information 
processing20.Neuroradiological studies report modest cerebral atrophy and 
an increased occurrence of subcortical and brainstem lesions21,22. 
Neurophysiological studies of the CNS in diabetic patients have mostly 
involved measurements of evoked potential latencies. Increases in the 
latencies of evoked potentials of different modalities, including visual 
evoked potentials (VEPs), brainstem auditory evoked potentials (BAEPs) 
and somatosensory evoked potentials, have often been reported23. 
Neurophysiological alterations have also been described in animal 
models of diabetes, in particular in rats. Neurophysiological alterations 
have been reported in the CNS of diabetic rats24,25,26,27 by various studies, 
but the course of development is incompletely documented. 
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REVIEW OF LITERATURE 
HISTORY OF CLINICAL NEUROPHYSIOLOGY 28 
Carlo Metteucci, Professor of Physics in Pisa, Italy, investigated the 
localisation of electricity in a nerve muscle preparation and proposed the 
concept of electrophysiological based functioning of the nervous system. 
In 1850, Helmholtz succeeded in measuring the conduction velocity 
of nerve in frog by mechanically recording the muscle twitch. Employing 
the same procedure, the conduction velocity of median nerve was found to 
be 61.0 ± 5.1 m/s and that of sensory nerve 60 m/s. The first report of 
nerve action potential in response to median and ulnar nerve stimulation 
was published in 1937 by Eicher. The modern techniques of sensory nerve 
conduction measurements were developed a decade later. 
In 1942, James Goldseth at NorthWestern University in 
collaboration with James Fizell , developed a constant current stimulator. 
The investigation of war injuries by Herburt Jasper in Canada resulted in 
the development of monopolar needle electrode .Interaction between 
Jasper, Goldseth and Fizell paved the way for the development of clinically 
useful electromyography equipment which was introduced in 1948 by 
Goldseth. 
In 1944, Harvey and Kuffer applied nerve conduction studies in 
patients with peripheral neuropathy. Hodes, Laravee and German in 1948 
first calculated conduction velocity by stimulating nerve at different levels. 
Nerve stimulation techniques were used to study the effect of ischemia on 
11 
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nerve excitability and it was shown that the rate of impulse propagation 
slowed in ischemic nerve.   
In 1956, Simpson demonstrated slowing of nerve conduction in 
carpal tunnel syndrome and Lambert and Kaesar differentiated 
demyelinating from axonal neuropathy. 
PREVALENCE OF DIABETIC NEUROPATHY 
Diabetic neuropathy is the most common and troublesome 
complication of diabetes mellitus leading to great morbidity and resulting 
in a huge economic burden for diabetes care29. However, the progression of 
neuropathy can be reduced by early detection and intervention30 
In a prospective study of over 4400 diabetic out patients, Pirart J31 
reported an overall 12% prevalence rate of diabetic neuropathy in patients 
with newly diagnosed diabetes and the incidence of neuropathy increased 
with the duration of diabetes and after 25 years of diabetes, over 50% of 
patients had DN31. In another study32 it was reported prevalence of 
neuropathy was 5% in the 20 to 29 year old group and increased with age, 
reaching 44.2% in patients between 70 to 79 years of age. 
Prevalence is typically higher if ascertainment is based on 
electrophysiological measurements, but lowers if it is based on subjective 
symptoms and physical findings only. The prevalence of neuropathy also 
increases with age and increasing duration of diabetes9. Diabetic patients 
have a 12 times higher risk of amputations when compared with non-
diabetic subjects, due to diabetic neuropathy33. The presence of other 
12 
 19 
 
vascular complications such as peripheral vascular disease in diabetes 
increases the risk of diabetic foot complications34.  
ROLE OF ELECTROPHYSIOLOGICAL STUDIES IN DIABETIC 
NEUROPATHY 
              Evaluation of neuropathy is generally undertaken by 
electrophysiological measurements35 .According to San Antonio Conention 
of neuropathy the patient with diabetic neuropathy must have a sign or a 
symptom and an abnormal electrodiagnostic test36. Electrophysiological 
studies are more sensitive than clinical examinations as clinical 
examinations fail to offer quantitative results and the electrodiagnostic 
tests are the least variable non invasive measures of neuropathy. 
          Electrodiagnostic tests have widespread applications and are reliable, 
reproducible measures of peripheral nervous system function. They are 
objective measures that are relatively independent of patient effort or 
cooperation. Nerve Conduction Study (NCS) and needle 
Electromyography (EMG) are well accepted for the evaluation of DN 37,38. 
They are sensitive measures, able to detect abnormalities in diabetic 
patients that may not be clinically apparent.  
Electrophysiological measures of nerve function have been the 
mainstay of 'objective' assessment of neurological deficits in diabetic 
patients39. Some form of abnormality can be detected in the majority of 
patients. Symptoms do not necessarily correlate with the 
electrophysiological abnormalities 40 
13 
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Nerve conduction studies, primarily nerve conduction velocities are 
considered one of the most sensitive indices of the severity of 
neuropathy41. Nerve conduction tests are used to localize lesions and to 
describe the type and severity of the pathophysiologic process, including 
alterations in function that are not recognized clinically. Lehtinen JM  
et al42 had reported that clinical diabetic neuropathy is not common at 
diagnosis of Type 2 diabetes but disturbances in peripheral and autonomic 
nerve function as noted by electrophysiological and cardiovascular reflex 
method are often present at that stage. In Type 2 diabetic patients 
decreased Nerve Conduction Velocity (NCV) is probably one of the 
earliest neuropathic abnormalities and is often present even at diagnosis. 
Thereafter, slowing of NCV generally progresses at a steady rate of 
approximately 1 m/s/year and it shows a correlation with the duration of 
diabetes.43 
NERVE CONDUCTION STUDIES IN DIABETES 
In a study done on diabetic patients, reduced sensory nerve action 
potential (SNAP) amplitude was observed in the medial nerve in 70% of 
the patients, in the ulnar in 69% and in the sural nerve in 22%. No 
correlation was found between metabolic indices and nerve conduction 
study parameters. High percentages of newly diagnosed DM patients show 
signs of neuropathy, and upper limb nerve sensory NCS seem to be more 
sensitive in detecting it than lower limb NCS 44. 
In a study done on diabetics with and without neuropathy, the 
amplitude and nerve conduction velocity (NCV) were lowered in both 
groups, particularly in those with neuropathy. Estimation of conduction 
14 
 21 
 
velocity can be considered as more useful parameter than the measurement 
of amplitude in the diagnosis and evaluation of neuropathy in diabetics. 
Assessment of sensory nerve conduction in median nerve is a better 
indicator than that of ulnar nerve45 
The independent risk factors for DN were female gender, height, 
age, weight, HbA1C and duration of diabetes. The only parameter linearly 
related to all these nerve conduction measurements was duration of 
diabetes, where increased duration was associated with longer latency, 
lower amplitudes and lower NCVs 46. The attributes of NCS that are likely 
to be most useful are summated or averaged sensory nerve action potential 
amplitude and averaged motor NCV47. 
Biswas48 observed deterioration of motor nerve function without 
sensory nerve dysfunction in fairly controlled type 2 diabetic subjects with 
shorter duration of diabetes. 
Gregerson49 found that motor conduction may get reduced in 
diabetes and positive correlation was demonstrated between neglected 
diabetes control and slowing of motor conduction velocity. Fagerberg  
et al50 also demonstrated that motor conduction velocity decreases with 
duration of diabetes. 
           The recording of a nerve action potential of normal latency, 
amplitude, and wave form requires synchronous conduction in the large 
myelinated fibres51. In diabetic neuropathy, the sensory nerve potentials 
are characterized by reduced amplitude, a polyphasic shape and an 
increased latency of the initial peak. These alterations can also appear, 
15 
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though to a lesser degree, when a careful clinical examination of the 
nervous system is negative52 
BRAINSTEM AUDOTORY EVOKED POTENTIAL 
ABNORMALITIES IN DIABETES 
Central diabetic neuropathy is a newer concept and it can be 
detected by simple and non-invasive methods. One of these methods is 
brainstem auditory evoked potentials (BAEP)53,54 and interpretations of  
them.  By this method, functional and autonomic pathologies from the 
acoustic nerve to the upper part of the brainstem can be demonstrated at an 
early stage54. Lesions on these levels result in changes in BAEP amplitudes 
and latencies. Evaluation of these changes might help to determine early 
subclinical injuries restricted to the afore mentioned regions 55. 
Brainstem auditory evoked potentials in rats with streptozotocin-
induced diabetes 
Roberto Rubini et al56 studied Brainstem auditory evoked potentials 
(BAEPs) in streptozotocin (STZ)induced -diabetic rats and age-matched 
controls at 3 and 5 months from induction of the pathology. The diabetic 
status of the animals was kept uncontrolled throughout the study. Body 
weight and glycosylated haemoglobin were markedly altered in the 
diabetic animals (− 42% and + 120% of control values, respectively). 
Neurophysiological results showed an increase in the latency of the major 
components of BAEPs; this increase was clearly time-dependent for the 
peripheral component (peak I). The central component (peak IV) was also 
significantly delayed. However, no significant impairment of the central 
conduction time was demonstrated by examining the interpeak I–IV 
16 
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latency. In conclusion, BAEPs prove to be a useful non-invasive 
neurophysiological technique that may help unravel both the relative 
involvement of the central nervous systems in the course of diabetes 
mellitus, and the evolution of diabetic neuropathy. 
Evaluation of Central Neuropathy in Type II Diabetes Mellitus by 
Multimodal Evoked Potentials 
Hikmet Dolu et al57 conducted various electrophysiological tests in 
51 patients with type II DM and compared them with 30 age and sex 
matched healthy control subjects. Peripheral and cortical latencies of 
median and tibial somatosensory evoked potentials (SEP), bilateral I-III 
and I-V interpeak latencies (IPL) of brainstem auditory evoked potentials 
(BAEP), bilateral P100 latency of visual evoked potentials (VEP) and 
bilateral cortical latency and central motor conduction time of motor 
evoked potentials (MEP) were evaluated. They observed prolonged 
latencies suggestive of central neuropathy in DM type II. It has been 
shown that most of the electrophysiological parameters in patients with 
DM type II correlate with the duration of the disease, some of them with 
the age of the patient, and few of them with the onset of the disease and 
found out knowledge, there is no correlation between the 
electrophysiological parameters and the level of glycaemia or the degree of 
metabolic control. They concluded that central and peripheral neuropathies 
in DM are related to the duration of the disease and not to the degree of 
hyperglycaemia and metabolic control. 
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Auditory Brainstem Latencies In Type I (Insulin-Dependent) Diabetic 
Patients  
Jukka Virtaniemi et al58 studied  auditory brainstem latencies in 53 
type I diabetic patients and 42 randomly selected non diabetic control 
subjects, aged between 20 and 40 years. They found out that Wave V 
latencies were longer in diabetic patients when compared with those of 
control subjects at all repetition rates and concluded that delayed auditory 
brainstem latencies in type I diabetic patients are probably caused by the 
long duration of diabetes and the microvascular complications associated 
with it. 
Brainstem auditory evoked potentials study in patients with Diabetes 
mellitus 
Chi-Ren Huang et al59 analysed the correlation between brainstem-
auditory evoked potentials (BAEP) and nerve conduction (NC) studies in 
patients with diabetes mellitus (DM) and  retrospectively reviewed the 
results from the subjects who received  neurological screening test 
including BAEP and NC studies. A DM group and a control group were 
applied. The DM group was subdivided 4 subgroups including neuropathy, 
non-neuropathy, infarct and non-infarct. At the end of the study they 
concluded that Patients with DM have a prolongation in IPL I-III, 
especially in the neuropathy subgroup. This prolongation in IPL I-III 
would best be explained by acoustic neuropathy. The tibial motor, median 
sensory, and sural NC velocities correlated with the acoustic neuropathy in 
patients with DM. 
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Delayed Auditory Brainstem Responses in Diabetes Mellitus 
M.W Donald et al60 found that Diabetic patients have longer 
interpeak latencies in the brainstem auditory evoked responses than age-
matched controls. The delay is not related to clinical hearing loss or blood 
glucose level at the time of testing. Since waves I and II are normal in 
latency, the conduction velocity of the eighth nerve is not involved. The 
delay occurs between waves II and V, which would reflect altered 
transmission times in auditory brainstem and midbrain structures, and 
suggests the presence of a central neuropathy in patients with diabetes. 
 The observed delay in central transmission time in diabetics may be 
related to the pathological observations like degeneration of the ganglion 
cells and nerve fibres of the cerebrum, brainstem, and cerebellum-severe 
enough histologically to justify the use of the term "encephalopathy"11. 
Olsson et al 61 and Reske-Nielsen et al 11 on the basis of detailed 
pathoanatomic studies concluded that brain involvement is common in 
longstanding diabetes.  
Nerve conduction velocity and evoked potential latencies in 
streptozotocin diabetic rats 
Biessels GJ et al 62 observed that, in streptozotocin (STZ) diabetic 
rats, deficits in cerebral function develop gradually in the course of months 
and there is a significant deficit in nerve conduction velocity and evoked 
potential latencies. 
19 
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Kamal A et al 63 demonstrated learning deficits in experimentally 
induced diabetic rats develop in association with deficits in synaptic 
plasticity. In addition, deficits in impulse conduction velocity develop in 
the brain, as reflected in increased evoked potential latencies.  
          Masana Y et al64 and Sima AA et al65 found out that in diabetic rats 
there is a significant deficit in nerve conduction velocity and evoked 
potential latencies. They documented an increased interpeak latency III-V 
in the BAEP and VEP p1 latency found in diabetic rats 
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AIMS AND OBJECTIVES 
1. To study the effects of the involvement of peripheral and central 
nervous system in non insulin dependent diabetic individuals by 
doing nerve conduction studies and brainstem auditory evoked 
potentials and comparing it with controls. 
 
2. To assess whether the duration of the disease is related to the degree 
of damage to the nerve. 
 
3. To compare the involvement of peripheral and central nervous 
system damage. 
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MATERIALS AND METHODS 
The study was conducted during the year 2009 – 10 in the Institute 
of Physiology and Experimental Medicine, Madras Medical College, after 
getting permission from the Institutional Ethical Committee, Madras 
Medical College, Chennai. 
Type 2 diabetes mellitus patients of both sexes in the age group 
between 35 and 55, were included in the study. They were selected from 
the Diabetology outpatient department, Government General Hospital, 
Chennai – 600 003. All the participants were informed about the study and 
procedure in their native language and a written consent was obtained from 
them. Age and sex matched healthy subjects were used as controls. 
INCLUSION CRITERIA. 
 Age group 35 – 55 years, of both gender. 
 Type 2 Diabetic patients with or without symptoms of neuropathy. 
 Both recently diagnosed and chronic diabetic patients. 
 Patients on oral hypoglycemic agents or insulin or both. 
EXCLUSION CRITERIA 
 Hypertension. 
 Smoking and alcoholism. 
 History of head injury. 
 Drug intake (ototoxic drugs). 
 Ear surgery. 
22 
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 External ear / middle ear pathologies. 
 Conductive / mixed hearing loss. 
 Patients with other metabolic abnormalities causing neuropathy. 
 Patients on drugs leading to neuropathy. 
 Patients with cochlear implant / cardiac pacemeaker. 
MATERIALS  
STUDY GROUP   (Diabetics) 
40 type 2 Diabetes mellitus patients in 35-55 years age group. 
Subgroups 
Group I  - type 2 DM patients with duration of diabetes between 0-7 years. 
Group II - type 2 DM patients with duration of diabetes between 7-15 
 years. 
CONTROL GROUP  
40 age and sex matched healthy controls. The following tests were 
conducted in the study and control group 
1. Nerve conduction study of  
a. Median nerve of right upper limb – motor and sensory 
components. 
b. Tibial nerve (motor) of right lower limb. 
2. Brain stem auditory evoked potentials. 
Both the tests are conducted using RMS – EMG MEDICARE 
SYSTEMS. (Photograph 1) 
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Photograph 1. RMS – EMG Recorders Medicare Systems 
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PRECAUTIONS 
(1)  The subject should be properly instructed and motivated to provide 
full cooperation. 
(2)  The subject should be fully relaxed. 
(3)  The room should be quiet and comfortable. 
(4)  The subject should be grounded properly 
NERVE CONDUCTION STUDY 
PRINCIPLES OF MOTOR NERVE CONDUCTION28 
The motor nerve is stimulated at two points along its course. The 
pulse is adjusted to record a compound muscle action potential. Typically, 
the impulse is generated using a bipolar stimulator placed on the surface of 
the skin over the anatomic course of nerve being tested. The nerve is 
subjected to supramaximal stimulation keeping the cathode close to the 
active recording electrode. This prevents the hyperpolarisation effect of 
anode and anodal conduction block. The surface recording electrodes are 
used and placed in belly tendon montage, keeping the active electrode 
close to the motor point and reference to the tendon, ground electrode is 
placed between the stimulating and recording electrodes.  
A biphasic action potential with initial negativity is recorded. 
Surface stimulation of healthy nerve requires a square wave pulse of  
0.1 ms duration with an intensity of 5-40 ma (milliamperes). Filter setting 
for motor nerve conduction study is 5khz-10khz and sweep speed 
2-5 ms/division. 
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The measurement for motor nerve conduction study include the 
following  
 1. Onset latency. 
 2. Amplitude of compound muscle action potential (CMAP). 
 3. Duration of compound muscle action potential. 
 3. Nerve conduction velocity. 
ONSET LATENCY 
The onset latency is the time in ms from the stimulus artefact to the 
first negative deflection of CMAP. It is a measure of conduction in the 
fastest conducting motor fibres. It also includes the neuromuscular 
transmission time and the propagation time along the muscle membrane 
which constitute the residual latency. 
AMPLITUDE 
The amplitude of CMAP is measured from baseline to the negative 
peak (base to peak) or between negative and positive peaks (peak to peak). 
The amplitude correlates with number of nerve fibres. 
DURATION 
The duration of CMAP is measured from the onset of response to 
the negative or positive peak or the final return of waveform to the 
baseline. Duration correlates with the density of small fibres. 
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MOTOR NERVE CONDUCTION VELOCITY  
This is a measure of speed of impulse conduction. Motor nerve 
conduction velocity is calculated by measuring the distance between two 
points of stimulation in mm which is divided by the latency difference in 
millisecond. The nerve conduction velocity is expressed as m/sec 
(metre/second).  Measurement of latency difference between the two points 
of stimulation eliminates the effect of residual latency. 
Conduction velocity      
DLPL
D

 
PL----proximal latency in milliseconds (ms). 
DL----distal latency in milliseconds (ms). 
D----distance between proximal and distal stimulation in millimetres. 
For accurate motor nerve conduction velocity measurement, the 
distance between two points of stimulation should be at least 10 cm. This 
reduces the error due to faulty measurement. 
PRINCIPLES OF SENSORY NERVE CONDUCTION28  
The sensory nerve conduction can be measured orthodromically or 
antidromically. In orthodromic conduction, a distal portion of the nerve 
e.g. digital nerve is stimulated and sensory nerve action potential (SNAP) 
is recorded at a proximal point along the nerve. In antidromic sensory 
nerve conduction, the nerve is stimulated at a proximal point and nerve 
action potential is recorded distally. For orthodromic conduction ,ring 
electrodes are preferred to stimulate the digital nerve, whereas surface 
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stimulating electrodes are commonly used for antidromic conduction.The 
recommended filter settings for sensory conduction is 10Hz-2KHz, sweep 
speed 1-2ms/division and gain 1-5µv/division. The signal enhancement 
with averaging is generally required for sensory conduction velocity. The 
signal enhancement with averaging is proportional to the square root of the 
number of trials. 
               Change in amplitude =square root of n.  
               n= no of trials, which is kept at 20. 
EXPERIMENTAL PROCEDURE  
NERVE CONDUCTION STUDY – MEDIAN NERVE  
       Motor and sensory components were tested. 
MEDIAN NERVE (motor) 
         Recording electrode     : close to the motor point of abductor pollicis 
 brevis. 
         Reference electrode     : 3 cm distal to 1st metacarpo phalangeal joint. 
         Stimulation 1              : at wrist 3 cm proximal to distal wrist crease. 
        Stimulation 2       : at elbow near the volar crease of brachial  
  pulse.  
 Refer Fig: 1 
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Fig: 1. Electrode Placement for Motor Conduction of Median Nerve 
 
 
 
 
 
 
 
 
MEDIAN NERVE (sensory) 
Recording electrode  :  proximal interphalangeal joint. 
         Reference electrode   : distal interphalangeal joint. 
         Stimulation                 : wrist.    
Refer Fig.2   
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Fig 2. Electrode placement for orthrodomic sensory conduction of 
median nerve. 
 
 
TIBIAL NERVE (motor) 
Recording electrode   :  Abductor hallucis slightly below and 
 anterior  to navicular  tuberosity 
Reference electrode  :  5cm distal to the recording electrode. 
Stimulation 1            :  behind and proximal to the medial   
  malleolus. 
Stimulation 2            :  in the popliteal fossa along the flexor crease 
  of the knee slightly lateral to midline of the 
  popliteal fossa    
 Refer fig 3  
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Fig: 3. Electrode Placement for Motor Conduction of tibial Nerve. 
 
   
      
 
Photograph – 2 
Recording of nerve conductions parameters of median never (motor) 
in a diabetic 
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BRAINSTEM AUDITORY EVOKED POTENTIALS28. 
Brainstem auditory evoked potentials are the potentials recorded 
from the ear and vertex in response to a brief auditory stimulation to assess 
the conduction through the auditory pathway upto midbrain. Brainstem 
auditory evoked potentials comprise 5 or more peaks within 10 ms of the 
stimulus. 
The auditory nerve and brainstem auditory potentials are volume 
conduction to surface electrodes. At the vertex and earlobe, these form 
vertex positive and vertex negative waves which are known as brainstem 
auditory evoked potentials. The peak to peak amplitude of these waves 
recorded from the scalp are only about 1/00 the amplitude of ongoing 
spontaneous EEG activity. There are 5 or more distinct waveforms 
recorded within 10 ms of the auditory stimulus. 
Origin of brainstem auditory evoked potentials 
I           VIII   NERVE 
II          COCHLEAR NUCLEUS 
III         SUPERIOR OLIVORY NUCLEUS 
IV         LATERAL LEMNISCUS 
V          INFERIOR COLLICULI 
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INSTRUMENT SETTINGS FOR RECORDING BAEPs 
ELECTRODES 
 Surface electrodes were used to record electrophysiological signals 
produced in the auditory pathway in response to auditory stimulus. The 
electrodes were standard cup type silver – silver chloride electrodes of 
10mm diameter and 1.5 m in length. 
MONTAGE SETTINGS 
Active electrode         –       ipsilateral mastoid. 
Reference electrode   –       vertex (Cz). 
Ground electrode       -       contra lateral mastoid. 
AMPLIFIER AND AVERAGER. 
BAEPs are recorded using an amplification of 200000 - 500000. A 
10 ms epoch after the stimulus is averaged for BAEP recording and about 
2000 trials are averaged to get a good quality recording. Two repetitions 
are done and superimposed to get a good quality recording. 
FILTER SETTINGS 
Low frequency filter – 100 Hz, electrical activity with frequencies 
lower than 100 Hz like electroencephalogram activity or other low 
frequency electrical noise are filtered. 
High frequency filter – 3000 Hz. 
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AUDITORY STIMULATION 
Auditory stimulation is produced via headphones fitted to the 
person’s ear. The BAEPs are produced by a brief click stimulus which is a 
square wave pulse of 0.1 ms duration. 
     Click rate           – 11 Hz. 
     Click intensity   – 90 Db. 
     Masking             – white noise at 60 db intensity.          
PROCEDURE 
Using electrode paste, the recording electrode was placed at 
ipsilateral mastoid (the ear to which click stimulus is to be given) the 
reference electrode was placed at Cz midline in the vertex.  The ground 
electrode was placed in the contra lateral mastoid. The electrodes were 
connected to the pre–amplifier. The subject is asked not to move his/her 
head during the test. Refer Photograph 3 
 
 
 
 
 
 
 
Photograph - 3 
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RESULTS 
40 type 2 diabetic patients and 40 healthy controls were included in 
this study. Nerve conduction tests of median sensory, median motor and 
tibial motor were performed. Latency, amplitude and nerve conduction 
velocity were measured. 
 Brainstem auditory evoked potential of both the ears was tested. 
Absolute and interpeak latencies were measured. 
             Diabetic patients were divided into two groups based on duration 
of disease. 
Group 1 – 0-7    years diabetes duration (20 patients). 
Group 2 – 7- 15 years diabetes duration (20 patients). 
Results were analysed by student’s independent t-test. 
P –value was calculated to test the statistical significance. 
P- value <0.05 was considered significant. 
P- value <0.01 was considered highly significant. 
P- value <0.001 was considered very highly significant. 
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1) COMPARISON OF NERVE CONDUCTION VALUES BETWEEN 
 DIABETICS AND CONTROLS 
1.1  Comparison of latency of median nerve-sensory, median nerve-
motor and tibial nerve-motor between diabetics and controls. 
NERVE 
TESTED 
GROUPS 
NO OF 
SUBJECTS 
MEAN ± SD 
(ms) 
P-VALUE 
Median nerve- 
sensory 
Diabetic 40 4.14  ± 0.96 
<0.001 
Control 40 3.02 ± 0.32 
Median nerve- 
motor 
Diabetic 40 4.57 ± 1.29 
<0.001 
Control 40 3.56 ± 0.28 
Tibial nerve-
motor 
Diabetic 40 6.74 ± 1.32 
<0.001 
Control 40 5.11 ± 0.55 
P = < 0.001 is very highly significant 
 
There was a very highly significant increase in the latency of 
median nerve (sensory and motor) and tibial nerve (motor) in the diabetic 
group compared to the controls. 
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Comparison of latency of median nerve-sensory, median nerve-motor 
and tibial nerve-motor between diabetics and controls. (ms) 
Plate 1.1 
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1.2  Comparison of amplitude of median nerve-sensory, median 
 nerve-motor and tibial nerve-motor between diabetics and 
 controls. 
NERVE 
TESTED 
GROUPS 
NO OF 
SUBJECTS 
MEAN ± SD P-VALUE 
Median nerve- 
sensory  (µv) 
Diabetic 40 22.03 ± 4.50 
<0.001 
Control 40 33.96 ± 3.95 
Median nerve- 
motor (mv) 
Diabetic 40 3.69 ± 1.09 
<0.001 
Control 40 7.70 ± 1.22 
Tibial nerve 
motor  (mv) 
Diabetic 40 3.38 ± 0.61 
<0.001 
Control 40 4.23 ± 0.37 
P = < 0.001 is very highly significant 
There was a very highly significant decrease in the amplitude of 
median nerve (sensory and motor) and tibial nerve (motor) in the diabetic 
group compared to the controls. 
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Comparison of amplitude of median nerve-motor and tibial nerve-
motor between diabetics and controls. (mv) 
Plate 1.2a : 
 
 
Comparison of amplitude of median nerve-sensory between diabetics 
and controls. (µv)   plate 1.2b : 
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1.3  Comparison of NCV of median nerve-sensory, median nerve-
motor and tibial nerve-motor between diabetics and controls. 
NERVE 
TESTED 
GROUPS 
NO OF 
SUBJECTS 
MEAN ± SD 
(m/s) 
P-VALUE 
Median nerve- 
sensory  
Diabetic 40 47.92  + 3.73 
<0.001 
Control 40 55.21 + 3.01 
Median nerve- 
motor  
Diabetic 40 50.11 + 5.00 
<0.001 
Control 40 57.01 + 2.31 
Tibial nerve - 
motor 
Diabetic 40 39.42 + 3.91 
<0.001 
Control 40 47.26 + 1.10 
                                                    P = < 0.001 is very highly significant  
 There was a very highly significant decrease in the NCV of median 
nerve (sensory and motor) and tibial nerve (motor) in the diabetic group 
compared to the controls. 
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Comparison of NCV of median nerve-sensory, median nerve-motor 
and tibial nerve-motor between diabetics and controls. (m/s) 
Plate 1.3 
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2)  COMPARISON OF NERVE CONDUCTION VALUES WITHIN 
DIABETICS DIVIDED INTO GROUPS BASED ON DURATION. 
  Group 1 – 0-7  years duration (20 patients). 
Group 2 –7-15 years duration (20 patients).  
2.1  Comparison of latency of median nerve-sensory, median nerve-
motor and tibial nerve-motor between two groups of diabetics. 
S.NO GROUPS 
NO OF 
SUBJECTS 
MEAN ± SD 
(ms) 
P-VALUE 
Median nerve- 
sensory  
Group 1 20 3.71 ± 0.81 <0.01 
 Group 2 20 4.57± 0.93 
Median nerve- 
motor  
Group 1 20 4.13 ± 1.21 <0.05 
 Group 2 20 5.01 ± 1.24 
Tibial nerve - 
motor 
Group 1 20 6.25 ± 1.29 
<0.05 
Group 2 20 7.22 ± 1.18 
      P = < 0.01 is highly significant  
                            P = < 0.05 is significant  
There was a highly significant increase in the latency of median 
nerve (sensory) in group 2 compared to group 1. 
There was a significant increase in the latency of median nerve 
(motor) and tibial nerve (motor) in group 2 compared to group 1. 
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Comparison of latency of median nerve-sensory, median nerve-motor 
and tibial nerve-motor between two groups of diabetics. (ms) 
Group 1 – 0-7  years duration (20 patients). 
Group 2 –7-15 years duration (20 patients).  
Plate 2.1 
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2.2  Comparison of amplitude of median nerve-sensory, median 
nerve-motor and tibial nerve-motor between two groups of 
diabetics 
Group 1 – 0-7   years duration (20 patients). 
Group 2 –7-15  years duration (20 patients).  
S.NO GROUPS 
NO OF 
SUBJECTS 
MEAN ± SD P-VALUE 
Median nerve- 
sensory  (µv) 
Group 1 20 23.69 ± 4.37  
<0.05 
 
 
Group 2 20 20.36 ± 4.09 
Median nerve- 
motor (mv) 
Group 1 20 4.05 ± 0.92  
<0.05 
 
Group 2 20 3.33 ± 1.15 
Tibial nerve 
motor  (mv) 
Group 1 20 3.58 ± 0.66  
<0.05 
 
Group 2 20 3.19 ± 0.51 
P = < 0.05 is significant 
 
There was a significant decrease in the amplitude of median nerve (sensory 
and motor) and tibial nerve (motor) in group 2 compared to group 1. 
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Comparison of amplitude of median nerve-motor and tibial nerve-
motor between two groups of diabetics.  plate 2.2a  
 
 
 
Comparison of amplitude of median nerve sensory between two 
groups of diabetics  plate 2.2b   
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2.3  Comparison of NCV of of median nerve-sensory, median nerve-
motor and tibial nerve-motor between two groups of diabetics. 
Group 1 – 0-7   years duration (20 patients). 
Group 2 –7-15 years duration (20 patients).  
S.NO GROUPS 
NO OF 
SUBJECTS 
MEAN ± SD 
(m/s) 
P-VALUE 
Median nerve- 
sensory  
Group 1 20 49.62 ± 3.35 
<0.01 
Group 2 20 46.23 ± 3.36 
Median nerve- 
motor  
Group 1 20 51.69 ± 4.64 
<0.05 
Group 2 20 48.53 ± 4.95 
Tibial nerve - 
motor 
Group 1 20 41.11 ± 3.86 
<0.01 
Group 2 20 37.48 ± 3.25 
     P = < 0.01 is highly significant  
     P = < 0.05 is significant 
There was a highly significant decrease in the NCV of median nerve 
(sensory) and tibial nerve (motor) in group 2 compared to group 1. 
There was a significant decrease in the NCV of median nerve 
(motor) in group 2 compared to group 1. 
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Comparison of NCV of of median nerve-sensory, median nerve-motor 
and tibial nerve-motor between two groups of diabetics.  (m/s) 
Group 1 – 0-7   years duration (20 patients). 
Group 2 –7-15  years duration (20 patients).  
Plate 2.3 
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BAEP RESULTS  
3.1  Comparison of absolute latencies of BAEP between diabetics 
and controls – RIGHT EAR: 
BAEP 
LATENCY 
(ms) 
GROUP 
NO OF 
SUBJECTS 
MEAN ± SD P -value 
WAVE -I 
Diabetic 40 1.49 ± 0.05  
0.539 
Control 40 1.48 ± 0.05 
WAVE -II 
Diabetic 40 2.73 ± 0.10 
 
0.088 
Control 40 2.77 ± 0.09 
WAVE -III 
Diabetic 40 3.79 ± 0.14 
 
<0.001 
Control 40 3.56 ± 0.05 
WAVE -IV 
Diabetic 40 4.95 ± 0.10 
 
0.404 
Control 40 4.93 ± 0.06 
WAVE -V 
Diabetic 40 6.24 ± 0.42 
 
<0.001 
Control 40 5.69 ± 0.06 
P = < 0.001 is very highly significant  
        P = >0.05 not significant 
There was a very highly significant increase in the absolute latency 
of wave III and V in diabetics compared to the controls. 
There was no significant difference in the absolute latency of wave 
I, II and IV in diabetics compared to the controls. 
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Comparison of absolute latencies of BAEP between diabetics and 
controls.  
RIGHT EAR: 
Plate 3.1 
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3.2  Comparison of absolute latencies of BAEP between diabetics 
and controls –LEFT EAR: 
BAEP 
LATENCY 
(ms) 
GROUP 
NO OF 
SUBJECTS 
MEAN ± SD 
(ms) 
P -value 
WAVE -I 
Diabetic 40 1.50 ± 0.06 
0.315 
Control 40 1.48 ± 0.04 
WAVE -II 
Diabetic 40 2.76 ± 0.11 
0.935 
Control 40 2.76 ± 0.15 
WAVE -III 
Diabetic 40 3.79 ± 0.21 
<0.001 
Control 40 3.58 ± 0.06 
WAVE -IV 
Diabetic 40 4.97 ± 0.12 
0.125 
Control 40 4.94 ± 0.06 
WAVE -V 
Diabetic 40 6.25 ± 0.44 
<0.001 
Control 40 5.70 ± 0.07 
  P = < 0.001 is very highly significant  
        P = >0.05 not significant  
There was a very highly significant increase in the absolute latency 
of wave III and V in diabetics compared to the controls. 
There was no significant difference in the absolute latency of wave 
I, II and IV in diabetics compared to the controls. 
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Comparison of absolute latencies of BAEP between diabetics and 
controls. 
LEFT EAR: 
Plate 3.2 
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3.3 Comparison of interpeak latencies of BAEP between diabetics 
and controls 
RIGHT EAR: 
BAEP 
LATENCY 
(ms) 
GROUP 
NO OF 
SUBJECTS 
MEAN ± 
SD(ms) 
P - value 
I-III 
INTERPEAK 
LATENCY 
Group 1 40 2.30 ± 0.17 
 
<0.001 Group 2 40 2.08 ± 0.07 
I-III 
INTERPEAK 
LATENCY 
Group 1 40 4.75 ± 46 
 
<0.001 Group 2 40 4.20± 0.08 
I-III 
INTERPEAK 
LATENCY 
Group 1 40 2.45 ± 0.32 
 
<0.001 Group 2 40 2.12 ± 0.09 
 P = < 0.001 is very highly significant  
 
There was a very highly significant increase in the I-III, I-V, and III-
V interpeak latency of diabetics compared to the controls. 
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Comparison of interpeak latencies of BAEP between diabetics and 
controls 
RIGHT EAR: 
Plate 3.3 
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3.4 Comparison of interpeak latencies of BAEP between diabetics 
 and controls 
LEFT EAR: 
BAEP 
LATENCY 
(ms) 
GROUP 
NO OF 
SUBJECTS 
MEAN + SD 
(ms) 
P-value 
I-III 
INTERPEAK 
LATENCY 
Diabetic 40 2.29 ± 0.25 
 
<0.001 Control 40 2.09 ± 0.08 
I-V 
INTERPEAK 
LATENCY 
Diabetic 40 4.75 ± 0.48 
 
<0.001 Control 40 4.21 ± 0.09 
III-V 
INTERPEAK 
LATENCY 
Diabetic 40 2.46 ± 0.35 
 
<0.001 Control 40 2.12 ± 0.09 
P = < 0.001 is very highly significant  
There was a very highly significant increase in the I-III, I-V, and III-
V interpeak latency of diabetics compared to the controls. 
 
 
 
 
44 
 61 
 
3.4 Comparison of interpeak latencies of BAEP between diabetics 
and controls 
 
LEFT EAR: 
Plate 3.4 
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4.1  Comparison of absolute latencies of BAEP within diabetics 
divided into groups based on duration 
Group 1 – 0-7   years duration (20 patients). 
Group 2 –7-15  years duration (20 patients).  
Right ear: 
BAEP 
LATENCY 
(ms) 
GROUP 
NO OF 
SUBJECTS 
MEAN 
±SD(ms) 
P -value 
WAVE -I 
Group 1 20 1.50 ± 0.05 
0.08 
Group 2 20 1.47 ± 0.05 
WAVE -II 
Group 1 20 2.71 ± 0.10 
0.246 
Group 2 20 2.75 ± 0.11 
WAVE -III 
Group 1 20 3.77 ± 0.16 
0.447 
Group 2 20 3.81 ± 0.12 
WAVE -IV 
Group 1 20 4.94 ± 0.09 
0.920 
Group 2 20 4.95 ± 0.12 
WAVE -V 
Group 1 20 6.08 ± 0.31 
<0.05 
Group 2 20 6.41 ±  0.46 
 P = < 0.05 is significant 
P = > 0.05 is not significant 
There was a significant increase in the absolute latency of wave V in 
group 2 compared to group 1. 
There was no significant difference in the absolute latency of wave 
I, II, III, and IV in group 2 compared to group 1. 
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Comparison of absolute latencies of BAEP within diabetics divided 
into groups based on duration. 
Group 1 – 0-7    years duration (20 patients). 
Group 2 –7-15  years duration (20 patients).  
Right ear: 
Plate 4.1 
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4.2 Comparison of absolute latencies of BAEP within diabetics 
divided into groups based on duration 
Group 1 – 0-7   years duration (20 patients). 
Group 2 –7-15  years duration (20 patients).  
Left Ear:  
BAEP 
LATENCY 
(ms) 
GROUP 
NO OF 
SUBJECTS 
MEAN 
±SD(ms) 
P -value 
WAVE -I 
Group 1 20 1.51 ±  0.06 
0.084 
Group 2 20 1.48±   0.05 
WAVE -II 
Group 1 20 2.75 ±  0.11 
0.723 
Group 2 20 2.77±   0.12 
WAVE -III 
Group 1 20 3.79±   0.16 
0.971 
Group 2 20 3.79±   0.26 
WAVE -IV 
Group 1  20 4.97 ±   0.11 
0.863 
Group 2 20 4.97 ±  0.13 
WAVE -V 
Group 1 20 6.05±   0.34 
<0.01 
Group 2 20 6.46±   044 
P = < 0.01 is highly significant    
  p = > 0.05 is not significant  
There was a highly significant increase in the absolute latency of 
wave V in group 2 compared to group 1. 
There was no significant difference in the absolute latency of wave 
I, II, III, and IV in group 2 compared to group 1. 
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Comparison of absolute latencies of BAEP within diabetics divided 
into groups based on duration. 
Group 1 – 0-7    years duration (20 patients). 
Group 2 –7-15   years duration (20 patients).  
 
Left Ear:  
Plate  4.2 
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4.3 Comparison of interpeak latencies of BAEP within diabetics 
divided into groups based on duration 
Group 1 – 0-7    years duration (20 patients). 
Group 2 –7-15   years duration (20 patients).  
Right Ear:  
BAEP 
LATENCY 
(ms) 
GROUP 
NO OF 
SUBJECTS 
MEAN ±SD(ms) P -value 
I-III 
INTERPEAK 
LATENCY 
Group 1 20 2.27 ± 0.19 
0.253 
Group 2 20 2.33 ±  0.15 
I-V 
INTERPEAK 
LATENCY 
Group 1 20 4.57 ± 0.34 
<0.05 
Group 2 20 4.93 ± 0.50 
III-V 
INTERPEAK 
LATENCY 
Group 1 20 2.30 ± 0.18 
<0.01 
Group 2 20 2.60 ± 0.36 
 P = < 0.01 is highly significant.  
      P = < 0.05 is significant. 
      P = > 0.05 is not significant. 
There was a highly significant increase in III-V interpeak latency in 
group 2 compared to group 1. 
There was a significant increase in I-V interpeak latency in group 2 
compared to group 1. 
There was no significant diference in I-III interpeak latency in  
group 2 compared to group 1. 
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Comparison of interpeak latencies of BAEP within diabetics divide 
into groups based on duration 
Group 1 – 0-7    years duration (20 patients). 
Group 2 –7-15   years duration (20 patients). 
  
Right Ear:  
Plate 4.3 
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4.4 Comparison of interpeak latencies of BAEP within diabetics 
divided into groups based on duration 
Group 1 – 0-7    years duration (20 patients). 
Group 2 –7-15   years duration (20 patients).  
Left Ear:  
BAEP 
LATENCY 
(ms) 
GROUP 
NO OF 
SUBJECTS 
MEAN 
±SD(ms) 
P -value 
I-III 
INTERPEAK 
LATENCY 
Group 1 20 2.27 ± 0.21 
0.701 
Group 2 20 2.31 ±  0.28 
I-V 
INTERPEAK 
LATENCY 
Group 1 20 4.53  ±  0.39 
<0.01 
Group 2 20 4.93  ±  0.47 
III-V 
INTERPEAK 
LATENCY 
Group 1 20 2.25 ±  0.18 
<0.001 
Group 2 20 2.67  ±  0.36 
P=<0.001 very highly significant. 
   P = < 0.01 is highly significant. 
P = > 0.05 is not significant. 
There was a very highly significant increase in III-V interpeak 
latency in    group 2 compared to group 1. 
There was a highly significant increase in I-V interpeak latency in 
group 2 compared to group 1. 
There was no significant difference in I-III interpeak latency in 
group 2 compared to group1. 
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Comparison of interpeak latencies of BAEP within diabetics divide 
into groups based on duration 
Group 1 – 0-7    years duration (20 patients). 
Group 2 –7-15   years duration (20 patients). 
  
Left Ear:  
Plate 4.4 
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Number of diabetics with nerve conduction abnormality 
Nerve conduction parameters affected 
Type 2 Diabetics -  40 patients. 
Controls               - 40 healthy individuals. 
Nerve 
Prolonged latency Reduced amplitude Decreased NCV 
Diabetics Control Diabetics Control Diabetics Control 
Median 
nerve - 
sensory 
22 0 18 0 24 0 
Median 
nerve - 
motor 
20 0 17 0 23 0 
Tibial 
nerve - 
motor 
24 0 20 0 26 0 
 
Nerve conduction parameters were most affected in the tibial nerve 
(motor). 
There were no nerve conduction abnormalities in the controls. 
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Nerve Conduction Results within Diabetics Groups 
Group 1 –  0-7   years diabetes duration (20 patients). 
Group 2 – 7-15 years diabetes duration (20 patients). 
 Nerve 
Prolonged 
latency 
Reduced 
amplitude 
Decreased 
NCV 
Group 
1 
Group 
2 
Group 
1 
Group 
2 
Group 
1 
Group 
2 
Median nerve - 
sensory 
8 14 7 11 9 15 
Median nerve - 
motor 
7 13 6 11 9 14 
Tibial nerve - 
motor 
9 15 8 12 10 16 
 
Number of diabetics with abnormal (increase) BAEP latency 
S.NO GROUP 
NO OF 
SUBJECTS 
BAEP LATENCY 
ABNORMALITY 
PRESENT ABSENT 
1 DIABETICS 40 22 18 
2 GROUP 1 20 8 12 
3 GROUP 2 20 14 6 
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DISCUSSION 
Nerve conduction studies and BAEP are simple, sensitive and 
objective technique for evaluating impulse conduction along the peripheral 
and central nervous systems. The present study deals with the 
abnormalities in nerve conduction study and BAEP in non insulin 
dependent diabetes mellitus patients.              
In our study nerve conduction parameters of sensory and motor 
component of median nerve and motor component of tibial nerve were 
studied unilaterally (right side). In several clinical trials, nerve conduction 
studies were often used, and were shown to be symmetrical in patients with 
diabetic sensory and sensorimotor polyneuropathy, thus justifying 
unilateral evaluation 66. 
NERVE CONDUCTION ABNORMALITIES IN DIABETICS  
Diabetic neuropathy (DN) is a common complication of DM and it 
is encountered in more than one third of diabetic patients67.  Pirart J31 had 
found a fivefold increase in the incidence of DN after 25 years of follow 
up. Discordance between nerve conduction studies and symptoms and 
signs of DN had been reported before 68, 69. In our study we found out 
abnormalities in all the parameters of nerve conduction study in diabetics 
when compared with controls. 
In our study a statistically significant difference was noted between 
the study group and control group in latencies of all the nerves tested viz., 
sensory and motor division of median nerve and tibial nerve. We also 
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observed a significant decrease in the amplitude and nerve conduction 
velocity of all the nerves tested in diabetics when compared with controls. 
Both latency and nerve conduction velocity depend on an intact, 
myelinated nerve as myelin and the saltatory conduction are essential for 
fast action potential propagation in normal subjects. In contrast, the 
amplitude of the waveform depends primarily on number of axons 
functioning within the nerve. Slowing of conduction velocity or 
prolongation of latency usually implies demyelinating injury, while loss of 
amplitude usually correlates with axonal loss or dysfunction 7. 
       In our study it was found out that latency and nerve conduction 
velocity were more affected than amplitude which is explained by the fact 
that DN is predominantly demyelinating 70,71. 
Among the nerves tested tibial nerve was most affected with 26 of 
the 40 diabetics showing abnormal conduction parameters. The 
involvement of sensory and motor division of median nerve was almost 
uniform, 24 diabetics with median sensory neuropathy and 23 with median 
motor neuropathy. The tibial nerve involvement can be explained by the 
fact that distal polyneuropathy is the most common neuropathy in DM and 
lower limb nerves are more involved than the upper limbs72. The uniform 
involvement of sensory and motor division of median nerve can be 
evidenced by the studies conducted by Fagerberg et al50, Gregersen49 and 
Bril73 who reported that motor defects are common in diabetics with 
neuropathy and increase in frequency with the duration of the disease. Jun 
Kimura et al 74 reported distal slowing of motor nerve conduction velocity 
in diabetic polyneuropathy. 
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EFFECT OF DURATION ON NERVE CONDUCTION 
PARAMETERS 
Though people with diabetes can develop neurological problems at 
any time, the risk of developing neuropathy increases with the duration of 
diabetes 75. In our study we found that duration of the disease had an 
influence on the nerve conduction parameters and found that latency delay 
and reduction in amplitude and nerve conduction velocity of the tested 
nerves was of greater degree in diabetics with longer duration (7-15 years) 
and were statistically significant when compared with diabetics in the 0-7 
years duration group. It was also found that mean amplitude of the nerves 
tested were normal in 0-7 year diabetic group whereas latency and NCV 
showed abnormalities even in this group. This could be explained by 
previous studies which stated that in diabetic neuropathy of shorter 
duration, segmental demyelination may be the only abnormal finding 76, 
whereas combined axonal and myelin changes suggesting wallerian 
degeneration are found in chronic or severe cases 77. 
  In a study done by Abdulsalam A et al78, the affected nerve 
conduction parameters in early diabetics were latencies and NCVs, 
whereas the amplitudes of sensory and motor responses were not 
significantly different from the control. This suggests that the early 
diabetic effects on the peripheral nerves were mainly demyelinating. 
The reduction in amplitude of nerve potential with duration may be 
explained by axonal injury. This could be the result either of a conduction 
block in fibres demyelinated for a long distance or of the degeneration of a 
number of axons79. 
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As per the previous studies, the severity of neuropathy increases 
with age and duration of diabetes 80. Aaron I Vinik found that duration of 
diabetes correlated with all three nerve conduction parameters 46. 
BAEP LATENCIES IN DIABETES 
In our study we found out that about 22 diabetics showed BAEP 
latency abnormalities. In our study, the absolute latencies of wave III and 
wave V and the interpeak latencies I-III, I-V and III-V were increased in 
DM group which showed a significant statistical difference when 
compared with the control group. The absolute latencies of wave I and 
wave II were normal in the study group suggesting that eighth nerve 
transmission time was normal in the diabetics. The increase in wave III 
latency and interpeak latency I – III with normal wave I and II latency 
indicates that there may be a dysfunction in the lower brainstem. 
Involvement of brainstem is also evidenced by an increase in absolute 
latency of wave V, I-V and III-V interpeak latencies .The BAEP findings 
of this study indicates that there may be involvement of brain stem in 
diabetic patients as evidenced by previous studies.57, 81, 82 
             In our study we also found out the impact of diabetes duration on 
BAEP latencies .The latency prolongation is more pronounced in 7-15 
(group I) years disease duration group compared to 0-7 years group  
(group II). The latency of wave V and interpeak latencies III–V and I-V 
showed a significant statistical difference among the above two groups. 
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This finding can be supported by the studies conducted by  
M W Donald et al60 and Ashok Verma et al 83. In the study conducted by 
M W Donald et al60 the mean duration of illness was 16 years and he 
observed a prolongation of III, V latencies and I-III , I-V interpeak 
latencies. In the study conducted by Ashok Verma et al 83 the mean 
duration of illness was 6 years and there was no increase in BAEP 
latencies among the diabetics. Olsson et al61 and Reske-Nielsen et al11 on 
the basis of detailed pathoanatomic studies, concluded that brain 
involvement was common in long standing diabetes. 
ABNORMALITIES IN NERVE CONDUCTION AND BRAINSTEM 
AUDITORY EVOKED POTENTIALS IN DIABETICS. 
In the present study it was found that both BAEP latency and nerve 
conduction parameters showed significant abnormality in diabetic 
individuals. BAEP abnormality was observed only in those subjects with 
abnormal nerve conduction parameters. A correlation between the BAEP 
findings and nerve conduction studies has been suggested, including 
velocity of median sensory and peroneal motor nerve in previous 
studies84,85. Chi-Ren Huang et al 59 reported that patients with DM had a 
delay in IPL I-III and IPL I-V in BAEP studies, especially in the 
neuropathy subgroup.      
The peripheral neuropathy associated with diabetes mellitus is 
responsible for a myriad of syndromes. Whether a specific involvement of 
central nervous system also occurs, has been questioned. Major text books 
on diabetes either disregard cerebral involvement or minimise its 
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existence86, 87.  However, a suggestion has been made recently that 
subclinical involvement occurs in diabetic patients13, 15. This study proves 
that there is involvement of central nervous system in diabetes as shown by 
increase in III, V absolute latencies and I-III ,I-V and III-V interpeak 
latencies which was also seen primarily in subjects with abnormal nerve 
conduction parameters  thus  suggesting  that  both  central and peripheral 
nervous are involved in diabetes mellitus. 
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SUMMARY 
40 type 2 diabetic individuals of both sex and 40 healthy controls 
were subjected to nerve conduction tests and brainstem auditory evoked 
potentials. 
There was a significant increase in the latencies of nerve conduction 
parameter in non insulin dependent diabetic individuals.  
There was a significant decrease in the amplitude and nerve 
conduction velocity of the peripheral nerves tested in diabetics. 
Brainstem auditory evoked potential also showed a significant 
increase in the absolute latencies of wave III and V and interpeak latencies 
of I-III, I-V and III-V. 
The latency delay and decrease in amplitude and nerve conduction 
velocity was significantly more pronounced in subjects with long duration 
of diabetes (7-15 years) when compared with short duration (0-7 years). 
The duration of diabetes had a profound effect on Brainstem 
auditory evoked potential which showed a statistically significant increase 
in the latency of wave V and I-V and III-V interpeak latencies. 
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CONCLUSION 
From this study it can be concluded that both the central and 
peripheral nervous systems are involved in diabetes mellitus as evidenced 
by an abnormal BAEP latencies and nerve conduction parameters. 
There was a significant worsening of the condition as the duration of 
the diabetes increases in both the central and peripheral nervous systems. 
This shows that there may be progressive demyelination occurring along 
with axonal loss or dysfunction (decrease in amplitude) in DM. 
This study suggests that periodic evaluation of diabetic individuals 
to such tests will help in monitoring the progress of neuropathy. 
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 91 
 
ANNEXURE – II 
PROFORMA FOR CONDUCTING THE STUDY ON EVALUATION 
OF NERVE CONDUCTION ABNORMALITIES AND BRAINSTEM 
AUDITORY EVOKED POTENTIAL IN TYPE 2 DIABETES. 
 
1. Name       : 
2. Age      : 
3. Sex      : 
4. Address     : 
5. Occupation     : 
6. Duration of diabetes             : 
    7.  Mode of treatment                               :  Insulin  
Oral hypoglycemic drugs (or) both  
    8. Any other associated illness 
(a) History of ischemic heart disease/stroke 
(b) History of hypertension                           
(c) History of smoking 
(d) History of alcoholism 
(e) History of any ototoxic drug intake 
(f) History of head injury 
(g) History of any ear surgery  
(h) History of numbness/pain  in the  Extremities 
(i) History of drug intake cuasing neuropahy 
(j) History of any endocrinopathy causing neuropathy 
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(k) Any vitamin deficiency                                      
9. General examination (including detailed central nervous system and 
 audiological examination )    
10.   Investigations 
1. FBS mg/dl           :                     
2. PPBS mg/dl         : 
 
11.  Date of conduct of experiment  : 
 
EXAMINATION OF NERVOUS SYSTEM 
 
A. SENSORY SYSTEM 
 
a. Touch: 
 
Perception:       0 - Normal 
1 - Decreased sensation 
2 - Increased sensation 
3 - Altered sensation 
 
Area affected:      1 - tips of fingers / toes 
2 - Entire finger / toes 
3 - Mid foot / hand 
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4 - Ankle / wrist 
5 - Lower 1/3rd leg 
6. Upper 2/3rd leg 
 
b. Pain:        N – Not affected 
Y – Affected 
 
 
Area affected       1 - tips of fingers / toes 
2 - Entire finger / toes 
3 - Mid foot / hand 
4 - Ankle / wrist 
5 - Lower 1/3rd leg 
6. Upper 2/3rd leg 
 
c). Position sense :     N- Not affected 
                                                         Y-Affected 
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B. MOTOR SYSTEM  
 
1. Nutrition :      1 - Normal 
2 – Wasting 
 
2. Power : Grade     1. No movement 
2. Flickering movement 
3. Present but not against  
 gravity 
4. Present against gravity 
 but   reduced 
5. Normal 
3. Reflexes :    
 
 AUDIOLOGICAL EXAMINATION 
 
1. Examination of the external auditory meatus 
2. Examination of the tympanic membrane  
3) Tuning fork tests : 
a) Rinne test :--------------------------------------- 
b) Weber test : ------------------------------------- 
c) Absolute bone conduction test : ---------------------- 
4) Pure tone audiometry : 
Right ear : -------------------------------------------------- 
Left ear : --------------------------------------------------- 
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ANNEXURE - III 
CONSENT FORM 
I Ms./Mrs./Mr.-------------------- understand that Dr.xxxxxxxxx, a 
Postgraduate student in Madras Medical College, Chennai is doing this 
study on ―evaluation of nerve conduction abnormalities and brainstem 
auditory evoked potential in Type 2 Diabetes Mellitus‖. I have been 
explained about the study in details. These tests are simple, involve the 
recording of evoked potential after giving visual stimulus. Nerve 
conduction study involves stimulation of the nerve by a very minimal 
current which is absolutely harmless. They do not involve injections or 
taking any medicines and are risk free. I am participating in this study 
willingly .I have not been forced to do so. I have also been told clearly that 
I could withdraw from this study without any prejudice.  
 
                                                                                  YOURS TRULY 
                                                                           (Signature of the subject) 
                                                  Name : ____________________________ 
                                                  Date and Time : _____________________ 
 
                       (TO BE FILLED BY THE SUBJECT AND PATIENTS) 
                              
                             (SIGNATURE OF RESEARCHER) 
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Nerve conduction study of median  nerve (sensory and motor ) and  tibial nerve (motor) in diabetic group.  
DD – diabetes duration  , LAT –latency, AMP – amplitude  and NCV – nerve conduction velocity. 
 
S.NO AGE SEX HT WT BMI DD 
MEDIAM NERVE 
SENSORY DIVISION 
 
MEDIAN NERVE 
MOTOE DIVISION 
TIBIAL NERVE 
LAT(ms) AMP(µv) NCV((m/s) LAT(ms) AMP(mv) NCV((m/s) LAT(ms) AMP(mv) NCV(m/s) 
1 45 M 165 74 27.18 4 4.26 18.5 45.86 5.39 2.4 44.74 6.94 3.2 41.52 
2 48 M 168 72 25.51 6 4.18 19.7 44.36 6.37 3.1 45.04 7.02 2.8 37.55 
3 37 F 155 68 28.30 5 4.58 16.3 48.16 5.25 2.8 46.76 8.15 2.9 39.62 
4 38 M 165 65 23.87 3 4.76 19.3 50.34 4.28 2.6 48.64 7.14 3.4 37.16 
5 42 M 166 62 22.49 2 4.86 20.8 44.68 5.17 2.7 46.24 6.88 2.6 34.56 
6 53 F 150 55 24.44 4 4.64 20.2 47.04 6.9 3 48.86 8.26 3 36.52 
7 42 M 168 73 25.86 5 5.28 15.7 46.64 5.62 4.4 50.06 7.22 2.7 40.03 
8 46 M 172 70 23.66 3 4.13 24.9 44.48 3.92 4.5 51.24 7.82 2.4 38.86 
9 52 F 164 60 22.30 6 2.93 27.3 46.36 3.66 4.9 42.55 7.96 3.6 36.64 
10 45 M 165 70 25.71 7 3.06 24.5 50.42 3.48 5.2 56.06 6.93 3.8 38.18 
11 46 F 160 65 25.39 5 2.83 28.3 52.82 3.76 5.3 54.86 4.38 4 37.01 
12 48 M 168 72 25.51 3 3.37 26.7 54.38 3.86 4.5 55.12 5.44 4.0 44.44 
13 50 F 162 66 25.14 7 3.15 28.5 54.06 3.23 4.7 57.14 5.04 4.5 46.54 
14 47 M 166 72 26.12 2 3.08 23.6 51.16 3.4 4.6 55.27 4.77 4.5 44.36 
15 39 F 155 64 26.63 3 3.64 24.6 50.82 3.21 4.8 54.78 4.56 4.4 45.12 
16 36 M 164 69 25.65 1 2.9 25.6 52.65 2.73 4.4 55.12 5.13 3.7 45.65 
17 41 M 172 78 26.36 4 2.58 26.3 51.06 3.33 4.5 56.25 5.3 4.1 45.05 
18 43 F 158 64 25.63 5 3.43 32.5 51.75 3.18 4.5 54.92 5.72 4 45.22 
19 45 F 155 62 25.80 3 3.66 25.2 52.02 3.15 4.1 54.88 5.46 3.8 43.84 
20 37 M 165 74 27.18 1 2.92 25.4 53.34 2.85 4 55.34 4.96 4.2 44.36 
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Nerve conduction study of median  nerve (sensory and motor ) and  tibial nerve (motor) in diabetic group.  
DD – diabetes duration  , LAT –latency, AMP – amplitude  and NCV – nerve conduction velocity. 
S.NO AGE SEX HT WT BMI DD 
MEDIAM NERVE 
SENSORY DIVISION 
MEDIAN NERVE 
MOTOE DIVISION 
TIBIAL NERVE 
LAT(ms) AMP(µv) NCV(m/s) LAT(ms) AMP(mv) NCV((m/s) LAT(ms) AMP(mv) NCV(m/s) 
21 55 M 16
5 
75 27.54 14 4.49 19.6 48.24 6.12 2.2 44.36 7.56 2.4 35.01 
22 53 M 16
7 
73 26.17 13 5.53 18.4 42.33 4.97 2.7 45.63 8.34 3 36.26 
23 54 F 15
4 
69 29.09 11 4.13 16.6 42.53 4.96 1.8 46.74 8.22 3.1 36.07 
24 54 F 16
4 
66 24.53 13 4.27 15.1 44.53 6.4 2.3 46.8 7.23 2.8 36.62 
25 55 M 16
5 
63 23.14 15 4.91 17.3 44.34 4.75 2.4 45.16 8.76 2.9 35.75 
26 55 M 14
8 
56 25.56 15 5.73 16.7 44.18 6.94 1.9 47.35 6.54 3 37.01 
27 50 M 16
6 
74 26.85 9 4.85 15.6 50.2 4.83 2 44.66 7.54 2.6 37.1 
28 54 M 17
0 
71 24.56 15 5.82 15.6 46.14 6.62 2.2 45.62 6.37 2.7 35.73 
29 52 F 16
2 
61 23.24 13 4.16 17.8 43.35 4.26 2.3 45.06 7.16 2.9 36.16 
30 49 M 16
3 
71 26.72 10 5.84 18.6 45.14 5.36 3.3 44.12 7.34 2.9 35.16 
31 47 F 15
8 
66 26.43 11 4.65 15.2 43.24 6.15 3 45.16 8.16 2.5 38.72 
32 48 M 16
6 
74 26.85 10 5.04 25.4 43.96 6.16 5 46.24 7.88 3 35.22 
33 50 M 16
0 
68 26.56 11 5.96 23.8 46.34 4.72 4.4 44.88 8.76 3.6 37.23 
34 47 M 16
7 
74 26.53 9 4.72 24.3 43.92 6.48 4.2 44.16 7.34 3.8 39.01 
35 47 F 15
6 
66 27.12 9 4.96 23.8 44.42 4.56 4.3 55.68 8.15 3.8 38.18 
36 45 F 16
5 
68 24.97 11 3.23 24.5 44.94 4.1 4.7 55.82 8.06 3.9 35.18 
37 44 M 17
3 
77 25.72 8 3.08 23.5 51.76 3.17 4.3 55.16 5.37 4.1 36.15 
38 46 F 15
9 
63 24.91 9 3.26 23.6 52.24 3.76 4.5 56.78 5.72 3.6 43.96 
39 45 F 15
6 
61 25.06 10 3.42 24.7 51.26 3.3 4.9 55.38 4.98 3.6 45.66 
40 47 M 16
6 
73 26.49 10 3.5 27.2 51.65 2.71 4.2 55.92 5.06 3.7 44.78 
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Nerve conduction study of media n nerve (sensory and motor), and  tibial nerve (motor) in control group. 
 
S.NO AGE SEX HT WT BMI 
MEDIAM NERVE 
SENSORY DIVISION 
MEDIAN NERVE 
MOTOE DIVISION 
TIBIAL NERVE 
LAT(ms) AMP(µv) NCV(m/s) LAT(ms) AMP(µv) NCV(m/s) LAT(ms) AMP(µv) NCV(m/s) 
1 45 M 160 72 28.12 2.67 28.8 61.42 3.4 6.1 59.38 5.44 4.4 46.56 
2 38 M 158 66 26.43 4.3 35.2 59.43 2.37 7.5 56.74 4.38 4.6 47.46 
3 42 M 165 70 25.71 3.1 37.6 61.02 3.14 8.6 57.58 5.62 4.8 46 
4 46 F 158 60 24.03 3.22 34.8 57.15 3.65 7.2 57.01 4.47 4 47.2 
5 47 M 170 72 24.91 2.57 38.6 53.82 2.96 9 59.12 5.5 4.5 46.9 
6 38 F 162 58 22.10 2.98 37 52.9 3.24 9.3 54.08 4.76 4.7 47.3 
7 41 M 168 64 22.67 3.19 38.8 57.52 3.53 6.9 57.62 4.82 4.5 46.11 
8 42 M 176 75 24.21 3.12 30.8 55.28 3.48 9.4 56.33 4.93 3.6 48.18 
9 45 M 170 78 26.98 3.88 27.4 58.88 3.55 9.2 58.24 4.98 3.6 45.72 
10 36 F 165 65 23.87 2.9 30.4 57.78 3.7 7 56.98 5.12 4.1 47.02 
11 38 F 165 65 23.87 3.06 34.7 54.96 3.59 6.5 57.03 5.26 4.3 46.58 
12 40 F 160 64 25 3.04 35.7 55.23 3.82 9.4 60.13 5.38 3.9 48.59 
13 46 M 168 72 25.51 3.14 36.7 60.88 3.63 9.4 56.14 5.66 3.7 47.42 
14 42 M 170 71 24.56 3 37.4 54.32 3.45 9.6 54.34 5.76 3.8 45.2 
15 35 M 165 68 24.97 2.76 31.9 57.54 3.75 9.2 57.63 5.78 4.4 46.44 
16 37 M 168 78 27.63 2.98 31.3 51.84 3.6 8.3 50.14 5.8 4.8 48.42 
17 42 M 160 74 28.90 2.74 32 58.26 3.61 8.3 60.16 4.34 4.7 46.64 
18 39 M 158 70 28.04 2.98 33.2 54.2 3.51 7.7 54.38 4.46 4.5 47.58 
19 42 F 155 65 27.05 3.23 28.4 51.36 3.46 7.7 58.16 4.72 4.1 46.36 
20 43 F 153 62 26.48 2.97 32 56.04 3.58 5.5 55.63 4.88 4 48.56 
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Nerve conduction study of media n nerve (sensory and motor), and  tibial nerve (motor) in control group. 
 
S.NO AGE SEX HT WT BMI 
MEDIAM NERVE 
SENSORY DIVISION 
MEDIAN NERVE 
MOTOE DIVISION 
TIBIAL NERVE 
LAT(ms) AMP(µv) NCV(m/s) LAT(ms) AMP(µv) NCV(m/s) LAT(ms) AMP(µv) NCV(m/s) 
21 51 F 160 65 25.39 2.63 32.3 51.16 3.54 9 58.88 4.94 4.5 47.6 
22 42 M 170 74 25.60 3.23 31.1 55.06 3.43 8.4 59.64 4.92 4.7 46.68 
23 44 M 168 70 24.80 3.17 29.3 54.12 3.48 6.8 57.47 5.54 4.7 48.52 
24 45 F 150 58 25.77 3.06 33.8 54.37 3.86 6.2 58.02 5.72 4.3 48.14 
25 36 M 162 68 25.91 3.01 38.1 55.31 4 6.9 55.12 5.5 3.9 46.26 
26 40 F 155 68 28.30 2.83 36.5 57.32 3.57 8.6 56.77 4.5 4 46.53 
27 39 M 165 70 25.71 3.18 31.8 57.76 3.59 7.4 58.15 4.53 4.5 49.78 
28 41 M 160 72 28.12 3.14 29.4 56.72 4.08 7.1 56.31 4.59 4.1 46.23 
29 45 F 160 70 27.34 3.6 38.6 50.77 3.54 8.6 50.36 4.3 4.2 47.36 
30 43 M 168 82 29.05 2.9 38.1 54.79 3.7 6.1 58.18 4.27 3.8 46.79 
31 37 M 170 78 26.98 2.88 38.8 54.78 3.61 5.7 57.13 4.13 3.9 48.39 
32 36 F 155 68 28.30 2.78 29.8 56.54 3.52 8.9 58.16 5.72 4.1 48.08 
33 44 F 150 65 28.88 3.12 30.2 52.86 3.8 6.3 57.04 5.65 4.1 48.15 
34 50 F 160 55 21.48 2.8 38.2 48.72 3.46 5.8 52.48 6.68 3.6 44.65 
35 43 M 165 56 20.56 2.61 39.3 52.04 3.6 6.7 57.28 5.4 4.1 46.66 
36 46 M 168 76 26.92 3 30.2 53.34 3.8 7.3 59.19 5.32 5 48.44 
37 42 F 152 55 23.80 2.89 32.4 49.26 3.92 7.4 57.14 5.26 4.5 48.62 
38 39 F 155 60 24.97 2.68 33.2 55.32 3.88 8.4 57.73 5.17 4.5 49.21 
39 40 M 168 63 22.32 2.92 29.8 53.44 3.6 8.1 58.13 5.2 3.9 46.61 
40 42 M 165 71 26.07 2.75 44.8 54.98 3.57 9.3 60.46 5.22 4 47.58 
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Brainstem auditory evoked potential latencies in diabetic group – RIGHT EAR 
S.NO AGE SEX HT WT BMI DD 
BAEP LATENCY –RIGHT EAR   (ms) 
I II III IV V I-III I-V III-V 
1 45 M 165 74 27.18 4 1.46 2.73 3.9 4.98 6.4 2.44 4.94 2.5 
2 48 M 168 72 25.51 6 1.48 2.63 3.98 4.98 6.42 2.5 4.94 2.44 
3 37 F 155 68 28.30 5 1.48 2.56 4.02 4.86 6.5 2.54 5.02 2.48 
4 38 M 165 65 23.87 3 1.5 2.65 3.98 4.9 6.52 2.48 5.02 2.54 
5 42 M 166 62 22.49 2 1.42 2.72 3.96 4.8 6.42 2.54 5 2.46 
6 53 F 150 55 24.44 4 1.42 2.5 4 4.92 6.46 2.58 5.04 2.46 
7 42 M 168 73 25.86 5 1.52 2.5 3.98 4.82 6.4 2.46 4.88 2.42 
8 46 M 172 70 23.66 3 1.55 2.8 3.83 4.94 6.53 2.28 4.98 2.7 
9 52 F 164 60 22.30 6 1.56 2.7 3.54 5.02 5.86 1.98 4.3 2.32 
10 45 M 165 70 25.71 7 1.6 2.86 3.7 5.08 5.8 2.1 4.2 2.1 
11 46 F 160 65 25.39 5 1.54 2.75 3.75 4.9 5.77 2.21 4.23 2.02 
12 48 M 168 72 25.51 3 1.52 2.68 3.55 4.96 5.8 2.03 4.28 2.25 
13 50 F 162 66 25.14 7 1.44 2.68 3.6 5.1 5.76 2.16 4.32 2.16 
14 47 M 166 72 26.12 2 1.52 2.8 3.65 5.02 5.94 2.13 4.42 2.29 
15 39 F 155 64 26.63 3 1.5 2.85 3.7 5.06 5.85 2.2 4.35 2.15 
16 36 M 164 69 25.65 1 1.48 2.75 3.74 4.76 5.86 2.26 4.38 2.12 
17 41 M 172 78 26.36 4 1.52 2.76 3.81 4.85 5.92 2.29 4.4 2.11 
18 43 F 158 64 25.63 5 1.57 2.78 3.55 4.94 5.84 1.98 4.27 2.29 
19 45 F 155 62 25.80 3 1.52 2.7 3.62 5.02 5.86 2.1 4.34 2.24 
20 37 M 165 74 27.18 1 1.58 2.82 3.72 5.06 5.78 2.14 4.2 2.06 
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Brainstem auditory evoked potential latencies in diabetic group – RIGHT  EAR. 
S.NO AGE SEX HT WT BMI DD 
BAEP LATENCY –RIGHT EAR   (ms) 
I II III IV V I-III I-V III-V 
21 55 M 165 75 27.54 14 1.46 2.65 3.88 5.08 6.5 2.42 5.04 2.62 
22 53 M 167 73 26.17 13 1.44 2.68 3.86 5.06 6.74 2.42 5.3 2.88 
23 54 F 154 69 29.09 11 1.5 2.68 3.94 5.04 6.81 2.44 5.31 2.87 
24 54 F 164 66 24.53 13 1.44 2.71 3.9 4.92 6.76 2.46 5.32 2.86 
25 55 M 165 63 23.14 15 1.44 2.66 3.84 4.82 6.77 2.4 5.33 2.93 
26 55 M 148 56 25.56 15 1.43 2.72 3.88 4.9 6.74 2.45 5.31 2.86 
27 50 M 166 74 26.85 9 1.4 2.6 3.82 4.9 6.7 2.42 5.3 2.88 
28 54 M 170 71 24.56 15 1.42 2.74 3.9 4.82 6.78 2.48 5.36 2.88 
29 52 F 162 61 23.24 13 1.48 2.62 3.92 4.76 6.76 2.44 5.28 2.84 
30 49 M 163 71 26.72 10 1.46 2.74 3.94 4.82 6.8 2.48 5.34 2.86 
31 47 F 158 66 26.43 11 1.42 2.94 3.84 5.06 6.78 2.42 5.36 2.94 
32 48 M 166 74 26.85 10 1.44 2.82 3.88 5.08 6.8 2.44 5.36 2.92 
33 50 M 160 68 26.56 11 1.52 3.08 3.96 5.08 6.4 2.44 4.88 2.44 
34 47 M 167 74 26.53 9 1.56 2.77 3.77 4.92 6.51 2.21 4.95 2.74 
35 47 F 156 66 27.12 9 1.54 2.7 3.53 4.94 5.7 1.99 4.16 2.17 
36 45 F 165 68 24.97 11 1.46 2.7 3.58 5.12 5.65 2.12 4.19 2.07 
37 44 M 173 77 25.72 8 1.56 2.84 3.67 5.04 5.75 2.11 4.19 2.08 
38 46 F 159 63 24.91 9 1.54 2.85 3.7 5.08 5.78 2.16 4.24 2.08 
39 45 F 156 61 25.06 10 1.52 2.77 3.72 4.76 5.84 2.2 4.32 2.12 
40 47 M 166 73 26.49 10 1.56 2.76 3.76 4.84 5.72 2.2 4.16 1.96 
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Brainstem auditory evoked potential latencies in diabetic group – LEFT EAR. 
S.NO AGE SEX HT WT BMI DD 
BAEP LATENCY –RIGHT EAR   (ms) 
I II III IV V I-III I-V III-V 
1 45 M 165 74 27.18 4 1.48 2.6 3.92 5.06 6.42 2.44 4.94 2.5 
2 48 M 168 72 25.51 6 1.42 2.68 3.96 5.02 6.44 2.54 5.02 2.48 
3 37 F 155 68 28.30 5 1.46 2.67 4 4.76 6.52 2.54 5.06 2.52 
4 38 M 165 65 23.87 3 1.48 2.74 4.02 4.98 6.5 2.54 5.02 2.48 
5 42 M 166 62 22.49 2 1.46 2.8 3.98 4.86 6.44 2.52 4.98 2.46 
6 53 F 150 55 24.44 4 1.42 2.58 3.96 4.92 6.48 2.54 5.06 2.52 
7 42 M 168 73 25.86 5 1.44 2.5 4 4.88 6.42 2.56 4.98 2.42 
8 46 M 172 70 23.66 3 1.52 2.88 4 4.94 6.43 2.48 4.91 2.43 
9 52 F 164 60 22.30 6 1.58 2.76 3.68 5.04 5.88 2.1 4.3 2.2 
10 45 M 165 70 25.71 7 1.54 2.88 3.64 5.14 5.8 2.1 4.26 2.16 
11 46 F 160 65 25.39 5 1.6 2.78 3.73 4.96 5.7 2.13 4.1 1.97 
12 48 M 168 72 25.51 3 1.54 2.68 3.55 4.98 5.7 2.01 4.16 2.15 
13 50 F 162 66 25.14 7 1.53 2.78 3.6 5.14 5.72 2.07 4.19 2.12 
14 47 M 166 72 26.12 2 1.48 2.9 3.69 5.06 5.77 2.21 4.29 2.08 
15 39 F 155 64 26.63 3 1.58 2.92 3.7 5.12 5.8 2.12 4.22 2.1 
16 36 M 164 69 25.65 1 1.58 2.82 3.72 4.74 5.86 2.14 4.28 2.14 
17 41 M 172 78 26.36 4 1.59 2.76 3.78 4.88 5.74 2.19 4.15 1.96 
18 43 F 158 64 25.63 5 1.5 2.8 3.8 4.94 5.78 2.3 4.28 1.98 
19 45 F 155 62 25.80 3 1.62 2.7 3.56 5.04 5.86 1.94 4.24 2.3 
20 37 M 165 74 27.18 1 1.54 2.9 3.66 5.12 5.76 2.12 4.22 2.1 
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Brainstem auditory evoked potential latencies in diabetic group – LEFT EAR. 
S.NO AGE SEX HT WT BMI DD 
BAEP LATENCY –RIGHT EAR   (ms) 
I II III IV V I-III I-V III-V 
21 55 M 165 75 27.54 14 1.44 2.66 3.88 5.14 6.52 2.44 5.08 2.64 
22 53 M 167 73 26.17 13 1.42 2.7 3.86 5.14 6.76 2.44 5.34 2.9 
23 54 F 154 69 29.09 11 1.44 2.68 3.9 5.04 6.84 2.46 5.4 2.94 
24 54 F 164 66 24.53 13 1.42 2.74 3.88 4.96 6.8 2.46 5.38 2.92 
25 55 M 165 63 23.14 15 1.46 2.7 3.92 4.84 6.82 2.46 5.36 2.9 
26 55 M 148 56 25.56 15 1.45 2.68 3.9 4.86 6.78 2.45 5.33 2.88 
27 50 M 166 74 26.85 9 1.52 2.6 3.84 4.84 6.76 2.32 5.24 2.92 
28 54 M 170 71 24.56 15 1.46 2.8 3.89 4.8 6.8 2.43 5.34 2.91 
29 52 F 162 61 23.24 13 1.56 2.62 3.98 4.76 6.82 2.42 5.26 2.84 
30 49 M 163 71 26.72 10 1.52 2.72 3.98 4.82 6.86 2.46 5.34 2.88 
31 47 F 158 66 26.43 11 1.42 2.94 3.86 5.16 6.8 2.44 5.38 2.94 
32 48 M 166 74 26.85 10 1.42 2.94 3.9 5.14 6.78 2.48 5.36 2.88 
33 50 M 160 68 26.56 11 1.42 3.08 3.94 5.06 6.42 2.52 5 2.48 
34 47 M 167 74 26.53 9 1.48 2.75 3.92 4.98 6.6 2.44 5.12 2.68 
35 47 F 156 66 27.12 9 1.56 2.66 3.55 5 5.74 1.99 4.18 2.19 
36 45 F 165 68 24.97 11 1.49 2.74 3.71 5.1 5.82 2.22 4.33 2.11 
37 44 M 173 77 25.72 8 1.6 2.84 3.68 5.04 5.86 2.08 4.26 2.18 
38 46 F 159 63 24.91 9 1.54 2.91 3.72 5.1 5.85 2.18 4.31 2.13 
39 45 F 156 61 25.06 10 1.52 2.8 2.78 4.78 5.9 1.26 4.38 3.12 
40 47 M 166 73 26.49 10 1.55 2.84 3.81 4.88 5.82 2.26 4.27 2.01 
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Brainstem auditory evoked potential latencies in  control group  
S.NO 
BAEP LATENCIES –RIGHT EAR BAEP LATENCIES –LEFT EAR 
I II III IV V I-III I-V III-V I II III IV V I-III I-V III-V 
1 1.46 2.76 3.68 5.04 5.82 2.22 4.36 2.14 1.48 2.8 3.7 5.02 5.86 2.22 4.38 2.16 
2 1.44 2.8 3.7 5.08 5.76 2.26 4.32 2.06 1.46 2.8 3.74 5.04 5.78 2.28 4.32 2.04 
3 1.5 2.78 3.66 5.02 5.6 2.16 4.1 1.94 1.51 2.82 3.66 5.04 5.6 2.15 4.09 1.94 
4 1.44 2.82 3.62 4.94 5.66 2.18 4.22 2.04 1.44 2.78 3.65 4.96 5.65 2.21 4.21 2 
5 1.44 2.8 3.54 4.86 5.75 2.1 4.31 2.21 1.44 2.84 3.54 4.9 5.75 2.1 4.31 2.21 
6 1.43 2.76 3.56 4.9 5.8 2.13 4.37 2.24 1.46 2.8 3.58 4.92 5.82 2.12 4.36 2.24 
7 1.4 2.7 3.6 4.92 5.68 2.2 4.28 2.08 1.42 2.72 3.62 4.88 5.7 2.2 4.28 2.08 
8 1.42 2.84 3.48 4.88 5.72 2.06 4.3 2.24 1.44 2.82 3.54 4.9 5.74 2.1 4.3 2.2 
9 1.48 2.78 3.58 4.8 5.7 2.1 4.22 2.12 1.46 2.82 3.58 4.82 5.72 2.12 4.26 2.14 
10 1.46 2.8 3.6 4.9 5.7 2.14 4.24 2.1 1.46 2.84 3.62 4.92 5.74 2.16 4.28 2.12 
11 1.42 3 3.58 5 5.62 2.16 4.2 2.04 1.42 2.96 3.6 5.02 5.62 2.18 4.2 2.02 
12 1.44 2.9 3.54 5.02 5.66 2.1 4.22 2.12 1.42 2.93 3.58 5 5.66 2.16 4.24 2.08 
13 1.45 3.02 3.46 5 5.74 2.01 4.29 2.28 1.46 2 3.48 5.02 5.78 2.02 4.32 2.3 
14 1.46 2.7 3.56 4.94 5.85 2.1 4.39 2.29 1.46 2.99 3.55 4.96 5.9 2.09 4.44 2.35 
15 1.48 2.68 3.52 4.96 5.52 2.04 4.04 2 1.5 2.7 3.54 4.98 5.54 2.04 4.04 2 
16 1.5 2.6 3.48 4.86 5.7 1.98 4.2 2.22 1.5 2.64 3.5 4.9 5.7 2 4.2 2.2 
17 1.5 2.65 3.62 4.9 5.6 2.12 4.1 1.98 1.5 2.66 3.62 4.92 5.62 2.12 4.12 2 
18 1.42 2.76 3.68 4.8 5.65 2.26 4.23 1.97 1.4 2.76 3.7 4.8 5.66 2.3 4.26 1.96 
19 1.42 2.56 3.55 4.94 5.64 2.13 4.22 2.09 1.42 2.56 3.55 4.92 5.64 2.13 4.22 2.09 
20 1.52 2.58 3.56 4.84 5.68 2.04 4.16 2.12 1.54 2.6 3.56 4.84 5.7 2.02 4.16 2.14 
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S.NO 
BAEP LATENCIES –RIGHT EAR BAEP LATENCIES –LEFT EAR 
I II III IV V I-III I-V III-V I II III IV V I-III I-V III-V 
21 1.56 2.7 3.6 4.92 5.64 2.04 4.08 2.04 1.53 2.7 3.58 4.9 5.62 2.05 4.09 2.04 
22 1.54 2.78 3.58 4.96 5.72 2.04 4.18 2.14 1.54 2.76 3.6 4.98 5.72 2.06 4.18 2.12 
23 1.46 2.72 3.56 5.04 5.65 2.1 4.19 2.09 1.48 2.74 3.58 5 5.65 2.1 4.17 2.07 
24 1.52 2.68 3.6 4.94 5.75 2.08 4.23 2.15 1.5 2.7 3.64 4.96 5.78 2.14 4.28 2.14 
25 1.44 2.88 3.53 4.98 5.78 2.09 4.34 2.25 1.44 2.88 3.55 4.94 5.8 2.11 4.36 2.25 
26 1.52 2.78 3.59 4.86 5.64 2.07 4.12 2.05 1.52 2.79 3.59 4.88 5.68 2.07 4.16 2.09 
27 1.56 2.8 3.65 4.84 5.72 2.09 4.16 2.07 1.52 2.8 3.68 4.82 5.7 2.16 4.18 2.02 
28 1.55 2.84 3.61 4.94 5.68 2.06 4.13 2.07 1.52 2.84 3.64 4.92 5.64 2.12 4.12 2 
29 1.46 2.72 3.57 4.93 5.66 2.11 4.2 2.09 1.44 2.74 3.58 4.94 5.65 2.14 4.21 2.07 
30 1.6 2.8 3.54 4.94 5.8 1.94 4.2 2.26 1.56 2.82 3.54 4.94 5.8 1.98 4.24 2.26 
31 1.54 2.78 3.52 4.94 5.77 1.98 4.23 2.25 1.54 2.8 3.54 4.9 5.75 2 4.21 2.21 
32 1.52 2.7 3.48 4.98 5.78 1.96 4.26 2.3 1.48 2.74 3.5 5.02 5.76 2.02 4.28 2.26 
33 1.44 2.8 3.46 4.86 5.6 2.02 4.16 2.14 1.48 2.82 3.42 4.9 5.58 1.94 4.1 2.16 
34 1.52 2.68 3.6 5.02 5.62 2.08 4.1 2.02 1.54 2.7 3.58 5.04 5.6 2.04 4.06 2.02 
35 1.5 2.86 3.58 4.92 5.7 2.08 4.2 2.12 1.5 2.84 3.6 4.94 5.72 2.1 4.22 2.12 
36 1.48 2.8 3.6 4.88 5.66 2.12 4.18 2.06 1.5 2.82 3.58 4.92 5.68 2.08 4.18 2.1 
37 1.52 2.8 3.55 4.85 5.72 2.03 4.2 2.17 1.57 2.82 3.52 4.88 5.7 1.95 4.13 2.18 
38 1.57 2.8 3.5 4.94 5.66 1.93 4.09 2.16 1.6 2.84 3.5 4.96 5.68 1.9 4.08 2.18 
39 1.52 2.78 3.56 4.97 5.72 2.04 4.2 2.16 1.54 2.78 3.58 4.99 5.7 2.04 4.16 2.12 
40 1.58 2.84 3.54 5.02 5.74 1.96 4.16 2.2 1.56 2.86 3.54 5.04 5.72 1.98 4.16 2.18 
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